The Panic-Proof Portfolio (Stockchase Research)GenMark DiagnosticsGNMKTOP PICKAug 18, 2020

Stockchase Research Editor: Michael O'Reilly This maker of COVID-19 test kits has just applied for Emergency Use Authorization of a new product that is better aligned to large batch testing. It can provide results for 96 samples in 5 hours. The stock has moved from $4 to over $20 since the pandemic outbreak. The recent pullback allows for an excellent entry level. We would trade this with a $13 stop-loss. Analysts at Needham increased the target to $22 (some 37% upside)-- the 5th such upgrade this year. Yield 0% (Analysts’ price target is $21.40)